Methotrexat Ebewe (Methotrexate Disodium)

Methotrexate, the active ingredient in Methotrexat Ebewe, is an antimetabolite (folate antagonist) presented as a sterile injectable solution for intramuscular, intravenous, subcutaneous use. It is employed in the treatment of certain cancers, autoimmune diseases and ectopic pregnancy. GNH USA supplies Methotrexat Ebewe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate acts on rapidly dividing cells and immune pathways, making it useful across several disease families. - Rheumatoid arthritis: reduces joint inflammation and disease progression. - Psoriasis: decreases skin cell proliferation and plaque formation. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell replication. - Non‑Hodgkin lymphoma: slows tumor growth through folate pathway blockade. - Breast cancer: used in combination regimens to limit tumor expansion. - Ectopic pregnancy: terminates trophoblastic tissue by disrupting DNA synthesis.

Methotrexate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting. - Fatigue or malaise. - Oral mucositis (mouth sores). - Mild liver enzyme elevation. - Transient low white blood cell count. - Skin rash or itching.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Profound bone marrow suppression leading to pancytopenia. - Life‑threatening infections due to immunosuppression. - Renal failure from crystal precipitation. - Rare anaphylactic reactions on injection.

Methotrexate requires careful monitoring and specific safety measures. - Pregnancy: contraindicated (Category X); avoid use in women of childbearing potential. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: perform baseline liver tests and monitor during therapy. - Hematologic monitoring: regular complete blood counts to detect myelosuppression. - Drug interactions: review concomitant medications for potential additive toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate can interact with several medicines, altering efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: increased risk of severe infection. - NSAIDs (e.g., ibuprofen, naproxen): heightened methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: enhanced myelosuppression.

Moderate Interactions (Monitor Closely): - Penicillins and sulfonamides: may increase plasma levels. - Phenytoin, carbamazepine: can reduce methotrexate effectiveness. - Alcohol: potentiates liver injury. - Proton pump inhibitors: may affect renal clearance.